European Guidelines for Anti-CGRP Migraine Prevention Drugs: What's Recommended
The European Headache Federation recommends all four anti-CGRP monoclonal antibodies for migraine prevention, based on low-to-high quality evidence for both episodic and chronic migraine.
Quick Facts
What This Study Found
The European Headache Federation formally recommends all four anti-CGRP monoclonal antibodies for migraine prevention. For episodic migraine, eptinezumab, erenumab, fremanezumab, and galcanezumab are recommended based on low to high quality evidence. For chronic migraine, erenumab, fremanezumab, and galcanezumab are recommended based on medium to high quality evidence.
One antibody (erenumab) targets the CGRP receptor, while the other three (eptinezumab, fremanezumab, galcanezumab) target the CGRP peptide itself. The guideline notes that for many clinical questions — like which patients to prioritize, when to switch between drugs, or how long to treat — evidence was insufficient and recommendations relied on expert opinion.
Key Numbers
4 monoclonal antibodies evaluated · Low–high quality evidence for episodic migraine · Medium–high quality evidence for chronic migraine · 1 targets CGRP receptor (erenumab) · 3 target CGRP peptide (eptinezumab, fremanezumab, galcanezumab)
How They Did This
The guideline was developed using the GRADE (Grading of Recommendation, Assessment, Development, and Evaluation) approach. The working group performed systematic literature review, assessed evidence quality, and formulated recommendations. Where evidence was insufficient for GRADE-based recommendations, expert opinion was used.
Why This Research Matters
This was the first official European guideline for anti-CGRP monoclonal antibodies in migraine, establishing them as evidence-based preventive treatments. CGRP is a peptide that plays a central role in migraine pathophysiology, and these antibodies represented the first migraine-specific preventive therapy class. The guideline gave clinicians an evidence-based framework for prescribing these drugs, which have since become a standard of care for patients who don't respond to traditional preventives.
The Bigger Picture
Anti-CGRP monoclonal antibodies were the first migraine-specific preventive treatments ever developed — previous options were all repurposed from other conditions (blood pressure drugs, antidepressants, anti-seizure medications). This guideline marked a turning point in migraine treatment, formally endorsing targeted peptide-pathway therapies. Since then, these drugs have become widely prescribed and the anti-CGRP class has expanded to include small-molecule CGRP receptor antagonists (gepants) for both prevention and acute treatment.
What This Study Doesn't Tell Us
Published in 2019, this guideline reflects early-stage evidence for these drugs — long-term safety and real-world effectiveness data were limited at the time. Several clinical questions (patient selection, switching between drugs, treatment duration) lacked sufficient evidence for formal recommendations. The guideline has likely been updated or supplemented since publication.
Questions This Raises
- ?How have real-world data since 2019 changed recommendations for patient selection and treatment duration?
- ?Which patients should receive anti-CGRP receptor antibodies (erenumab) versus anti-CGRP peptide antibodies?
- ?What is the long-term cardiovascular safety of chronically blocking CGRP, a peptide involved in vascular regulation?
Trust & Context
- Key Stat:
- 4 drugs recommended All four anti-CGRP monoclonal antibodies received positive recommendations for migraine prevention based on formal evidence review
- Evidence Grade:
- Strong evidence grade — this is a formal clinical practice guideline from a major professional society using GRADE methodology, the gold standard for evidence assessment. It synthesizes data from multiple randomized controlled trials.
- Study Age:
- Published in 2019. While this was groundbreaking as the first European anti-CGRP guideline, the evidence base has grown substantially since then. Updated guidelines and real-world data have supplemented these initial recommendations.
- Original Title:
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
- Published In:
- The journal of headache and pain, 20(1), 6 (2019)
- Authors:
- Sacco, Simona(8), Bendtsen, Lars, Ashina, Messoud(9), Reuter, Uwe, Terwindt, Gisela, Mitsikostas, Dimos-Dimitrios, Martelletti, Paolo
- Database ID:
- RPEP-04455
Evidence Hierarchy
Frequently Asked Questions
What is CGRP and why does blocking it prevent migraines?
CGRP (calcitonin gene-related peptide) is a peptide released by nerve fibers during migraine attacks. It causes blood vessels to dilate and triggers pain signaling and inflammation in the brain's protective membranes. Blocking CGRP or its receptor with monoclonal antibodies prevents this cascade from happening, reducing the frequency and severity of migraine attacks.
Which anti-CGRP drug should a migraine patient choose?
The guideline found that all four drugs are effective, and at the time of publication there wasn't enough evidence to recommend one over another for specific patient profiles. The choice often depends on practical factors like preferred injection frequency (monthly vs. quarterly), route (self-injection vs. infusion), and insurance coverage. Your neurologist can help determine the best fit.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04455APA
Sacco, Simona; Bendtsen, Lars; Ashina, Messoud; Reuter, Uwe; Terwindt, Gisela; Mitsikostas, Dimos-Dimitrios; Martelletti, Paolo. (2019). European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.. The journal of headache and pain, 20(1), 6. https://doi.org/10.1186/s10194-018-0955-y
MLA
Sacco, Simona, et al. "European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.." The journal of headache and pain, 2019. https://doi.org/10.1186/s10194-018-0955-y
RethinkPeptides
RethinkPeptides Research Database. "European headache federation guideline on the use of monoclo..." RPEP-04455. Retrieved from https://rethinkpeptides.com/research/sacco-2019-european-headache-federation-guideline
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.